Elevance Health (ELV) shares closed at US$320, with the stock showing a 1-day return of 0.94% and a 7-day decline of 6.69%, extending weaker performance over the past month and the past 3 months.
See our latest analysis for Elevance Health.
Looking beyond this week, Elevance Health’s share price return is weaker over the year, with a year to date share price decline of 9.67% and a 1 year total shareholder return of 17.81% in the red. This suggests momentum has been fading rather than building recently.
If this pullback has you reassessing where growth might come from in healthcare, it could be a good time to scan 27 healthcare AI stocks as a starting list of potential ideas.
With Elevance Health reporting revenue of US$199.1b and net income of US$5.7b, along with some valuation tools suggesting a possible discount, you have to ask: is this weakness a chance to buy, or is future growth already priced in?
Most Popular Narrative: 18.1% Undervalued
At a last close of $320, the most followed narrative on Elevance Health pegs fair value at $390.54, implying meaningful upside if those assumptions play out.
Elevance Health’s investment potential over the next 1-3 years lies in balancing risks associated with Medicaid declines, cost management, and regulatory uncertainties against growth opportunities in Medicare Advantage, value-based care, and digital health innovation. Its established market position and diversified portfolio provide resilience, but operational cost pressures and policy changes will be critical factors influencing performance.
If you want to see what sits behind that valuation gap according to NateF, the real story is how earnings, margins, and growth in key segments are expected to evolve together, and which business lines are assumed to carry most of the heavy lifting.
Result: Fair Value of $390.54 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, if Medicaid membership pressures persist or medical cost trends stay elevated for longer, that 18.1% undervaluation story could start to look a lot thinner.
Find out about the key risks to this Elevance Health narrative.
Next Steps
If this has you feeling torn between caution and optimism, do not wait for someone else to tell you what to think. Take a look at the 5 key rewards and decide whether those positives justify your own thesis on Elevance Health.
Looking for more investment ideas?
You have done the hard part by digging into Elevance Health, so do not leave potential ideas on the table when there are other angles to consider.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com